New, urgent warning about the ‘hidden risk' of e-cigarettes and vapes issued by scientists
E‑cigarettes were initially marketed as a sleek way to help people quit traditional cigarettes — but that promise has largely gone up in smoke.
Research shows that most adult smokers who try vaping end up using both, while many teens who never smoked are getting hooked on nicotine through vaping.
Roughly 11 million Americans vape regularly, and though vapes are still considered less harmful than cigarettes because they don't burn tobacco — the source of tar and many carcinogens — mounting evidence shows they're far from safe.
A new study — published in the journal ACS Central Science — revealed that e-cigarettes release a shocking amount of toxic metals.
Andrey Popov – stock.adobe.com
A new study — published Wednesday in the journal ACS Central Science — revealed that e-cigarettes release a shocking amount of toxic metals, with some producing more lead in a day's use than nearly 20 packs of traditional cigarettes.
'Our study highlights the hidden risk of these new and popular disposable electronic cigarettes — with hazardous levels of neurotoxic lead and carcinogenic nickel and antimony — which stresses the need for urgency in enforcement,' senior author Brett Poulin, an assistant professor in the UC Davis Department of Environmental Toxicology, said in a statement.
'These risks are not just worse than other e-cigarettes but worse in some cases than traditional cigarettes,' Poulin added.
The research was led by Mark Salazar, a PhD candidate in Poulin's lab, who wanted to know more about what his friend — a vaper — was putting into his body.
When he tested the disposable vape pod in the lab, he was stunned by the results.
'When I first saw the lead concentrations, they were so high I thought our instrument was broken,' Salazar said. 'That sparked us into looking further into these disposables.'
'When I first saw the lead concentrations, they were so high I thought our instrument was broken,' one researcher said.
fotofabrika – stock.adobe.com
Researchers took a good, hard look into seven types of disposable devices from three of the most popular brands — Esco Bar, Flum Pebble and ELF Bar.
They discovered 'these disposable devices have toxins already present in the e-liquid, or they're leaching quite extensively from their components into e-liquids and ultimately transferred to the smoke,' Salazar said.
Some of the devices contained nickel and antimony levels that could increase the risk of cancer, as well as lead and nickel emissions that could lead to brain and lung damage.
Equally worrying is that the newer, disposable vapes seemed to emit more toxic metals than earlier, refillable vapes.
The researchers urged more research and regulation around e-cigarettes, especially because the market is outpacing the science.
While New York and the federal government restricted the sale of flavored e-cigarettes or vapes in 2020, the ban has not really been enforced — and new e-cigarette products are continuously emerging.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
an hour ago
- Newsweek
Ozempic Linked to Significant Reduction in Dementia—Study
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Semaglutide, the active ingredient in diabetes medications Ozempic and Wegovy, was associated with a significantly reduced risk of developing Alzheimer's disease-related dementia among patients with type 2 diabetes, a recent study reported. A new study published in the Journal of Alzheimer's Disease analyzed the medical records of over 1.7 million U.S. adults and found that semaglutide users experienced a notably lower risk of dementia compared to patients treated with insulin, metformin, or older GLP-1 agonists. These findings, publicly released on Tuesday, come as researchers and clinicians continue to search for effective means to mitigate the growing dementia epidemic in the U.S. Ozempic is medicine for adults with type 2 diabetes that along with diet and exercise may improve blood sugar. Ozempic is medicine for adults with type 2 diabetes that along with diet and exercise may improve blood sugar. Photo by Steve Christo - Corbis/Corbis via Getty Images Why It Matters With over 6 million Americans diagnosed with dementia and more than 100,000 related deaths each year, the potential for semaglutide to meaningfully lower risk could have sweeping public health implications. Dementia does not have a cure, and nearly half of all cases are thought to be preventable by addressing risk factors like obesity, type 2 diabetes, and cardiovascular disease, the New York Post reported. Evidence supporting semaglutide's neuroprotective effects may inform future prevention strategies among high-risk populations in the U.S. What To Know Landmark Study Shows Sharp Risk Reduction Researchers at Case Western Reserve School of Medicine, National Institutes of Health and the MetroHealth System in Cleveland examined the health records of 1,710,995 U.S. patients with type 2 diabetes who had no prior diagnosis of Alzheimer's disease-related dementia (ADRD). The study used a statistical method simulating a randomized clinical trial, comparing dementia diagnoses among those prescribed semaglutide, insulin, metformin, and older GLP-1 receptor agonists. Patients treated with semaglutide had a 46 percent lower risk of developing ADRD than those receiving insulin, a 33 percent lower risk than those on metformin, and a 20 percent lower risk than those on earlier GLP-1 agonists. The effect was particularly pronounced for vascular dementia, one of the most common subtypes. No protective association was found for frontotemporal dementia or Lewy body dementia. Wide Demographic Impact Observed The protective association was consistent among subgroups, including younger and older patients, men and women, and those with and without obesity. Researchers found the risk reduction was especially evident among older adults and women. What is Semaglutide? Semaglutide is a glucagon-like peptide-1 receptor agonist that helps regulate blood sugar, lowers body weight, and offers cardiovascular benefits for patients with diabetes. The drug can help improve insulin sensitivity, protect blood vessels, and reduce inflammation in the brain. Important Study Limitations Authors acknowledged limitations, including reliance on administrative diagnosis codes, which are subject to underdiagnosis and misclassification, data on medication adherence, cognitive test scores, and genetic risk factors were unavailable. Variations in clinical practice and health care use variations could also affect findings. Researchers emphasized the need for preclinical and clinical studies to establish causal effects. Additional International Data A separate study by Oxford University, published in Lancet's eClinicalMedicine journal, analyzed more than 100 million U.S. medical records and found that Ozempic users experienced lower rates of cognitive decline and nicotine use compared to those on other diabetes medications. This study also did not find a higher risk of anxiety, depression, or other neurological and psychiatric conditions with Ozempic. The researchers emphasized that the results were limited to diabetic patients and require more rigorous randomized controlled trials. What People Are Saying The researchers of the study, in a news article published by the American Journal of Managed Care: "In a real-world population with T2D [type 2 diabetes] who had no prior diagnosis of AD/ADRD [Alzheimer disease/Alzheimer disease-related dementia], our study shows that semaglutide was associated with a significantly lower risk of overall ADRD incidence compared with other antidiabetic medications, including insulin, metformin, and other GLP-1RAs. Significant reductions were observed in older and younger patients, women and men, and patients with and without obesity." Howard Fillit, chief science officer of the Alzheimer's Drug Discovery Foundation, in comments to Reuters: "The answer to all those limitations is to do a randomized clinical trial, which is exactly what Novo is doing." What Happens Next Novo Nordisk, the maker of Ozempic, began testing semaglutide in patients with early Alzheimer's disease in 2021. The results are expected sometime this year. Do you have a story that Newsweek should be covering? Do you have any questions about this story? Contact LiveNews@
Chicago Tribune
2 hours ago
- Chicago Tribune
Nestle says it will remove artificial dyes from US foods by 2026
Nestle said Wednesday it will eliminate artificial colors from its U.S. food and beverages by the middle of 2026. It's the latest big food company making that pledge. Last week, Kraft Heinz and General Mills said they would remove artificial dyes from their U.S. products by 2027. General Mills also said it plans to remove artificial dyes from its U.S. cereals and from all foods served in K-12 schools by the middle of 2026. The move has broad support. About two-thirds of Americans favor restricting or reformulating processed foods to remove ingredients like added sugar or dyes, according to an AP-NORC poll. Both California and West Virginia have recently banned artificial dyes in foods served in schools. On Sunday, Republican Gov. Greg Abbott of Texas signed a bill requiring foods made with artificial dyes or additives to contain a new safety label starting in 2027. The label would say they contain ingredients 'not recommended for human consumption' in Australia, Canada, the European Union or the U.K. The federal government is also stepping up its scrutiny of artificial colors. In January, days before President Donald Trump took office, the U.S. regulators banned the dye called Red 3 from the nation's food supply, nearly 35 years after it was barred from cosmetics because of potential cancer risk. In April, Trump's Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary said the agency would take steps to eliminate synthetic dyes by the end of 2026, largely by relying on voluntary efforts from the food industry. Nestle has pledged to remove artificial dyes before. Early in 2015, the company said it would remove artificial flavors and colors from its products by the end of that year. But the promise didn't hold. Nestle said Wednesday it's been removing synthetic dyes from its products over the last decade, and 90% of its U.S. portfolio doesn't contain them. Among those that do is Nesquik Banana Strawberry milk, which is made with Red 3. Nestle said Wednesday it wants to evolve with its U.S. customers' changing nutritional needs and preferences. 'Serving and delighting people is at the heart of everything we do and every decision that we make,' Nestle's U.S. CEO Marty Thompson said in a statement.
Politico
2 hours ago
- Politico
Too hot for the electric grid to handle?
The heat wave scorching large swaths of the country is stressing out the aging electric grid, threatening rolling blackouts when people need air conditioning most. To help keep ACs humming, the Trump administration is allowing some fossil fuel power plants in the Southeast to exceed pollution limits. While not an unprecedented move during emergencies, it marks a big contrast with other solutions that have emerged in recent years — such as Texas' reliance on solar power to get through heat waves. President Donald Trump's strategy to lean on fossil fuels creates a feedback loop: The more natural gas and coal are burned for energy, the more carbon pollution enters the atmosphere. This pollution helps warm the planet — requiring more electricity to cool people off. And without long-term planning for clean, reliable backup power, the short-term need to beat the heat dominates. That's why Energy Secretary Chris Wright authorized Duke Energy to run some power plants in the Carolinas at maximum output as temperatures approach 100 degrees, writes Jeffrey Tomich. 'Americans should not be forced to wonder if their power grid can support their homes and businesses,' Wright said in a statement. The heat dome is bearing down on much of the eastern U.S., from northeast Texas to New England, driving triple-digit heat and humidity in some areas. Scores of cities are under heat advisories, and more than 40,000 customers in several New York City boroughs lost power earlier this week as the temperatures stressed the local electric grid. Extreme heat is the leading weather-related cause of death in the country, killing more U.S. residents each year than hurricanes, floods and tornadoes combined, federal data shows. And it's not an equal-opportunity killer. In addition to directly causing dehydration or heat stroke, extreme heat can also worsen underlying health conditions. Research shows that already vulnerable populations, such as those without permanent housing, are more likely to have chronic conditions such as diabetes or cardiovascular disease. Lack of access to AC, medical care or nutrition only worsens the problem. Hotter days also mean higher utility bills. The summer heat is expected to drive up residential electricity bills by about 3 percent to an average of $178 per month, according to an analysis by the U.S. Energy Information Administration. That number could be even higher if temperatures continue to soar, EIA noted. It's Wednesday — thank you for tuning in to POLITICO's Power Switch. I'm your host, Arianna Skibell. Power Switch is brought to you by the journalists behind E&E News and POLITICO Energy. Send your tips, comments, questions to askibell@ Today in POLITICO Energy's podcast: James Bikales breaks down why the Senate parliamentarian rejected certain provisions of the Energy and Natural Resources Committee's portion of Trump's megabill and what that means for its prospects. Power Centers Science agency booted from HQThe National Science Foundation has been kicked out of its headquarters in Alexandria, Virginia, to make space for the Department of Housing and Urban Development, write Robin Bravender and Ellie Borst. Where NSF employees will go next, they don't know. HUD Secretary Scott Turner announced the takeover today at a new conference, but offered no insights about where NSF employees would be relocated. He said his agency was moving in to start a new 'golden age.' Trump's newest plan to kill EPA grantsThe Trump administration is taking the unusual step of trying to cut funding and eliminate programs it dislikes by using routine administrative actions, write Jean Chemnick and Miranda Willson. The goal is to block billions in Environmental Protection Agency grants that the Biden administration had signed binding contracts to pay. But some scholars say Trump's mechanism is legally dubious at best. 'Their bureaucratic jujitsu is impressive, but it's also illegal,' said Jillian Blanchard with Lawyers for Good Government. How a little green law set off a political explosionThe European Commission set off a political cluster bomb last week when it suddenly declared it was killing a relatively minor rule on corporate greenwashing, writes James Fernyhough. The announcement came two days after the center-right European People's Party, the largest force in the European Parliament, sent a letter to the commission saying it wanted the law dead. That has fueled a growing sense among the center-left bloc that the right wing is controlling not just Parliament, but also the commission. In Other News June is the new July: Why intense summer heat is arriving earlier. $80 million, few rules: Louisiana's energy efficiency 'slush fund.' Subscriber Zone A showcase of some of our best subscriber content. The Trump administration plans to fast-track permits for deep-sea mining, despite warnings from conservation groups that too little is known about delicate ecosystems deep underwater. A federal judge blocked the Trump administration from freezing funds for electric vehicle charging stations in 14 states, a suspension that has become a flashpoint in Trump's bid to choke off congressionally approved spending. The White House and automakers are scrambling to adjust to China's tightening of restrictions on rare earth elements — a growing choke point in Trump's trade war. That's it for today, folks! Thanks for reading.
